iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.73−0.03 (-4.00%)
Close on Nov 13, 2026Market cap $47.05MP/E –Yield –
iBio operating margin
Operating margin is operating income as a percentage of revenue.
iBio's operating margin for the twelve months ending Sep 30, 2026 was -3491.0%. For fiscal 2026 it was -35141.0%, against -4650.5% the year before. The highest annual figure on record is -360.1% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -35141.0% | −30490.5 |
| FY2025 | Jun 30, 2025 | -4650.5% | +2742.4 |
| FY2024 | Jun 30, 2024 | -7392.9% | −5816.6 |
| FY2022 | Jun 30, 2022 | -1576.3% | −264.1 |
| FY2021 | Jun 30, 2021 | -1312.1% | −457.3 |
| FY2020 | Jun 30, 2020 | -854.9% | −72.5 |
| FY2019 | Jun 30, 2019 | -782.4% | +2421.9 |
| FY2018 | Jun 30, 2018 | -3204.3% | +418.6 |
| FY2017 | Jun 30, 2017 | -3622.8% | −2579.3 |
| FY2016 | Jun 30, 2016 | -1043.6% | −683.4 |
| FY2015 | Jun 30, 2015 | -360.1% | +1513.0 |
| FY2014 | Jun 30, 2014 | -1873.2% | −1211.1 |
| FY2013 | Jun 30, 2013 | -662.1% | +68.3 |
| FY2012 | Jun 30, 2012 | -730.4% | +1125.9 |
| FY2011 | Jun 30, 2011 | -1856.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -775.6% | +1172.4 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -5951.0% | +4255.0 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -2599.0% | −2221.9 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -2209.5% | −287.1 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -1948.0% | −1006.4 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -10206.0% | −9135.8 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -377.1% | +1311.7 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -1922.4% | −1660.9 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -941.6% | +3291.8 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -1070.2% | −65.4 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -1688.8% | +1880.7 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -261.5% | +248.3 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -4233.3% | −3518.0 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -1004.8% | −388.0 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -3569.4% | +5208.3 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -509.8% | +3826.5 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -715.4% | +3762.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -616.7% | +1623.1 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -8777.8% | −6022.9 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -4336.3% | −1711.1 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -4478.2% | +6159.6 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -2239.9% | +2193.5 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -2754.9% | −418.6 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -2625.2% | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -10637.8% | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -4433.3% | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -2336.3% | – |
See a number that looks wrong?